Tardio Jason 4
4 · Ovid Therapeutics Inc. · Filed Sep 14, 2022
Insider Transaction Report
Form 4
Tardio Jason
Chief Commercial Officer
Transactions
- Sale
Common Stock
2022-09-12$2.15/sh−17,344$37,290→ 0 total
Footnotes (1)
- [F1]The Reporting Person acquired the shares pursuant to the Issuer's employee stock purchase plan. These transactions were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Following the reported transaction, the Reporting Person will hold no ESPP shares.